Business
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
First Quarter 2026 Revenue Increased 13% Year-over-YearWARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026 and Business Highlights Helped a record of over 45,000 children in the first quarter of 2026Generated total revenue of $59.4 million for the
About this update from Orthopediatrics Corp.
[{"type":"image","alt":"OrthoPediatrics Corp.","displaySize":"","headline":null,"caption":"OrthoPediatrics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/29d424390c1c4ef384b72b889c10210b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Dk6YtiUIBoUDYOYLnGCeGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/29d424390c1c4ef384b72b889c10210b","width":300,"height":96}},"lazy":false},{"type":"text","content":"First Quarter 2026 Revenue Increased 13% Year-over-Year","length":55,"tagName":"p"},{"type":"text","content":"WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2026.","length":289,"tagName":"p"},{"type":"text","content":"First Quarter 2026 and Business Highlights","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Helped a record of over 45,000 children in the first quarter of 2026","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated total revenue of $59.4 million for the first quarter of 2026, up 13% from $52.4 million in the first quarter of 2025; domestic revenue increased 11% and international revenue increased 22% in the quarter","length":213,"tagName":"p"}]},{"val":[{"type":"text","content":"Grew worldwide Trauma & Deformity revenue 14% and worldwide Scoliosis revenue 13% in the first quarter of 2026 compared to the first quarter of 2025","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved adjusted EBITDA of $2.2 million in the first quarter of 2026, compared to ($0.4) million in the first quarter of 2025","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced first quarter 2026 free cash flow usage by 40% as compared to the same period in the prior year","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased full year 2026 revenue guidance to $263.0 million to $267.0 million from its prior range of $262.0 million to $266.0 million, representing growth of 11% to 13% compared to prior year","length":192,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":85...